The NewcelX Ltd. (Nasdaq: NCEL) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. NewcelX reports under the Exchange Act on Form 20-F and furnishes current reports on Form 6-K, offering investors structured insight into its operations as a Swiss clinical-stage biopharmaceutical and biotechnology company focused on neurodegenerative and metabolic diseases.
Through these filings, readers can follow key corporate events connected to the merger between NLS Pharmaceutics Ltd. and Kadimastem Ltd., which established NewcelX as a combined entity integrating cell-therapy platforms with neuroscience and small-molecule expertise. For example, a Form 6-K details the post-merger appointment of Kost Forrer Gabbay & Kasierer, a member of Ernst & Young, as the independent registered public accounting firm for the fiscal year ending December 31, 2025, and describes the prior engagement and dismissal of CBIZ CPAs, P.C., along with references to previously disclosed material weaknesses.
On Stock Titan, NewcelX filings such as annual reports on Form 20-F, interim and event-driven Form 6-K submissions, and related exhibits can be viewed alongside AI-powered summaries. These summaries are designed to highlight essential elements of lengthy documents, helping users quickly identify information on topics like accounting firm changes, internal control disclosures, merger-related details, and other governance matters discussed in the filings.
Investors researching NCEL can use this page to monitor how NewcelX describes its business, risk factors, financial reporting framework, and post-merger integration steps over time. Real-time updates from EDGAR combined with AI-assisted overviews aim to make complex regulatory content more accessible without replacing the need to review the full original filings.
NewcelX Ltd. (NCEL) entered into a binding term sheet for REA Holdings Inc.’s proposed acquisition of its worldwide Mazindol portfolio. The term sheet provides $500,000 in attributed upfront consideration: $30,000 in cash and the remainder in shares representing 9.4% of REA’s fully diluted equity following closing. NewcelX would also be eligible for up to $55 million in potential development, regulatory and commercial milestone payments and tiered royalties of 2% to 8% on annual global net sales.
The proposed transaction remains subject to definitive documentation, customary closing conditions, and applicable corporate and CVR requirements. After completion, REA would assume responsibility for future patent maintenance, development, regulatory activities, financing and commercialization costs arising from its operations, subject to definitive documentation. NewcelX states that its financial position raises substantial doubt about its ability to continue as a going concern.
NewcelX Ltd. (NCEL) is filing Post-Effective Amendment No. 3 to its Form F-1 to update and supplement a resale registration related to an existing committed equity facility with Alpha Capital Anstalt. The registration continues to cover the resale of up to 500,000 common shares, consisting of 19,230 commitment shares and up to 480,770 shares that NewcelX may sell to Alpha under a March 31, 2025 Common Share Purchase Agreement with a $25.0 million total commitment. NewcelX is not selling securities in this prospectus and will not receive proceeds from resales by Alpha, but may receive cash from any primary share sales it chooses to make to Alpha at 95% of the lower of the purchase-date low price or VWAP.
Common shares outstanding were 5,776,128 before the facility and would be 6,276,128 if all 500,000 registered shares are issued and resold. The company recently completed April and July 2026 PIPE financings, added merger-related pro forma financials for its combination with Kadimastem, and describes itself as a clinical-stage cell-therapy and regenerative-medicine company focused on stem-cell-derived therapies for Type 1 diabetes and neurodegenerative diseases.
NewcelX Ltd. (NCEL), a clinical-stage cell-therapy company focused on Type 1 diabetes, reported an interim net loss of $2.9 million for the six months ended June 30, 2026, compared with $11.3 million a year earlier, with no revenue in either period. Research and development expenses rose to $1.2 million and general and administrative expenses to $1.7 million, reflecting expanded operations after the Kadimastem merger and public company costs.
Cash and cash equivalents were $0.7 million as of June 30, 2026, after using $2.9 million in operating cash during the half-year; NewcelX subsequently raised $1.35 million in April and $1.4 million in July 2026 private placements and has access to a $25.0 million committed equity facility. Management discloses substantial doubt about the company’s ability to continue as a going concern without additional financing. Operationally, lead program NCEL-101 advanced through a successful FDA Type B pre-IND meeting, with positive feedback on a planned Phase 1/2a trial in Type 1 diabetes.
NewcelX Ltd. (NCEL), a Switzerland-incorporated biotechnology company, filed a Form D for a completed exempt offering under Rule 506(b) of Regulation D. The company offered equity securities, including common shares, warrants to purchase common shares, and the common shares issuable upon warrant exercise.
The total amount sold in the offering is $2,940,234, which the company states includes the exercise price of common shares underlying the warrants at an exercise price of $4.437 per share, with $0 remaining to be sold. No sales commissions or finders’ fees were reported. The date of first sale was July 3, 2026.
NewcelX Ltd. (NCEL), a Switzerland-based clinical-stage cell therapy company, has filed a Form F-3 to register for resale up to 694,268 Common Shares. These consist of 347,134 shares issued in a July 2026 private placement and 347,134 shares issuable upon exercise of related warrants.
The resale is by existing selling shareholders; no shares are being sold by NewcelX. NewcelX will not receive proceeds from shareholder resales, but could receive up to $1.54 million if the July 2026 warrants are exercised for cash. Its Common Shares trade on the Nasdaq Capital Market under the symbol “NCEL,” and 5,776,128 Common Shares were outstanding as of August 19, 2026.
NewcelX focuses on stem-cell-derived, off-the-shelf regenerative therapies, led by NCEL-101 for Type 1 diabetes, and also develops a DOXA small-molecule platform. The company highlights prior financings, including a $1.4 million July 2026 placement and a $1.35 million April 2026 PIPE, and reports a 2025 pro forma net loss of $6.716 million. NewcelX cautions that resale and future issuances could pressure its share price and dilute existing holders.
NewcelX Ltd. entered into definitive securities purchase agreements for a private placement financing with certain accredited investors. Investors agreed to purchase 347,134 common shares, or pre-funded warrants in lieu thereof, at $4.033 per share, plus common warrants to purchase up to 347,134 common shares at an exercise price of $4.437 per share. The common warrants have a five-year term. The transaction is expected to yield $1.4 million in gross proceeds, with approximately $1.5 million of additional gross proceeds possible upon full cash exercise of the common warrants.
NewcelX plans to use the net proceeds, together with its current cash and a previously announced $25 million equity line, primarily to advance NCEL-101, its lead Type 1 Diabetes program in collaboration with Eledon Pharmaceuticals, and for working capital and general corporate purposes. Closing is expected on or about August 14, 2026, subject to customary closing conditions. The company agreed for 60 days not to enter agreements to issue additional common shares or equivalents or to file registration statements, subject to customary exceptions, and will use reasonable best efforts to file a resale registration statement within 45 calendar days. The securities are being issued in reliance on Section 4(a)(2) and Rule 506(b) of Regulation D to accredited investors or qualified institutional buyers, without general solicitation.
NewcelX Ltd. entered into securities purchase agreements for a $1.4 million private equity financing. The company will sell 347,134 common shares at $4.033 per share, a 20% premium to the July 30, 2026 closing price, plus warrants to purchase 347,134 additional common shares at an exercise price of $4.437, equal to 132% of that closing price. The financing, which includes participation from existing shareholders, is expected to close on or about August 14, 2026, subject to customary closing conditions.
NewcelX plans to use the proceeds, together with its current cash and a previously announced $25 million equity line, primarily to advance NCEL-101, its stem-cell-derived Type 1 Diabetes program with Eledon Pharmaceuticals, and for working capital and general corporate purposes. The securities are being issued in a private placement under Section 4(a)(2) and Regulation D and are not registered under the Securities Act, so resale in the United States requires an effective registration statement or a valid exemption. Forward-looking statements highlight risks including regulatory outcomes, clinical development uncertainties, substantial doubt about the company’s ability to continue as a going concern, and its ability to maintain Nasdaq listing.
NewcelX Ltd. reports that the Brazilian Patent and Trademark Office has issued Patent Number 112018010946-0, protecting the manufacturing process for its lead stem-cell-derived therapy candidate NCEL-101 for type 1 diabetes through November 2036. This Brazil patent complements the existing U.S. patent portfolio and is described as strengthening NewcelX’s global intellectual property position and potential partnering opportunities.
The company highlights Brazil as a major type 1 diabetes market, with about 500,000 people living with the disease and prevalence growing at an estimated 4.4% annually. NewcelX also notes a recently completed FDA Type B Pre-IND meeting for NCEL-101 in combination with Eledon’s anti-CD40L antibody, tegoprubart, which it says provides a regulatory pathway toward initiating clinical trials, while risk disclosures reiterate that its financial position raises substantial doubt about its ability to continue as a going concern.